{"drugs":["Chirhostim","Secretin Human"],"mono":{"0":{"id":"930219-s-0","title":"Generic Names","mono":"Secretin Human"},"1":{"id":"930219-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930219-s-1-4","title":"Adult Dosing","mono":"<ul><li>administer an intravenous test dose of 0.1 mL (0.2 mcg if using 16 mcg vial or 0.4 mcg if using 40 mcg vial) of secretin; if no reaction has developed within 1 minute, administer the recommended dose by IV injection over 1 minute.<\/li><li><b>Disorder of pancreas; Diagnosis:<\/b> 0.2 mcg\/kg IV injection over 1 minute<\/li><li><b>Gastrinoma; Diagnosis:<\/b> 0.4 mcg\/kg IV injection over 1 minute<\/li><li><b>Pancreatogram; Adjunct:<\/b> 0.2 mcg\/kg IV injection over 1 minute<\/li><\/ul>"},"1":{"id":"930219-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in children "},"3":{"id":"930219-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Disorder of pancreas; Diagnosis<\/li><li>Gastrinoma; Diagnosis<\/li><li>Pancreatogram; Adjunct<\/li><\/ul>"}}},"3":{"id":"930219-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930219-s-3-9","title":"Contraindications","mono":"acute pancreatitis, until acute episode subsides <br\/>"},{"id":"930219-s-3-10","title":"Precautions","mono":"<ul><li>atopic allergy or asthma, history; give test dose<\/li><li>inflammatory bowel disease; may be hyporesponsive, producing a false positive result for pancreatic disease<\/li><li>liver diseases, alcoholic or other; greater-than-normal volume response to secretin stimulation may mask coexisting pancreatic disease; interpret results with caution<\/li><li>vagotomy, history; may be hyporesponsive, producing a false positive result for pancreatic disease<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930219-s-3-11","title":"Pregnancy Category","mono":"Secretin: C (FDA)<br\/>"},{"id":"930219-s-3-12","title":"Breast Feeding","mono":"Secretin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930219-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Flushing<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain, Nausea, Vomiting<\/li><\/ul>"},"6":{"id":"930219-s-6","title":"Drug Name Info","sub":{"0":{"id":"930219-s-6-17","title":"US Trade Names","mono":"Chirhostim<br\/>"},"2":{"id":"930219-s-6-19","title":"Class","mono":"Endocrine-Metabolic Agent<br\/>"},"3":{"id":"930219-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930219-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930219-s-7","title":"Mechanism Of Action","mono":"Synthetic human secretin is a peptide hormone with an amino acid sequence identical to naturally occurring secretin. The main action is to increase the secretion of pancreatic juice, including bicarbonate by stimulating the exocrine pancreas thereby assisting in the diagnosis of exocrine pancreatic dysfunction.<br\/>"},"8":{"id":"930219-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"930219-s-8-24","title":"Distribution","mono":"Vd: 2.7 L <br\/>"},"3":{"id":"930219-s-8-26","title":"Excretion","mono":"<ul><li>Renal clearance: 11 to 15 mL\/kg\/min<\/li><li>Total body clearance: 580.9 mL\/min<\/li><\/ul>"},"4":{"id":"930219-s-8-27","title":"Elimination Half Life","mono":"45 minutes <br\/>"}}},"9":{"id":"930219-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>(16 mcg vial) reconstitute in 8 mL Sodium Chloride Injection to a concentration of 2 mcg\/mL; shake vigorously<\/li><li>(40 mcg vial) reconstitute in 10 mL Sodium Chloride Injection to a concentration of 2 mcg\/mL; shake vigorously<\/li><li>administer test dose of 0.1 mL (0.2 mcg if using the 16 mcg vial or 0.4 mcg if using the 40 mcg vial); may give recommended dose if no allergic reaction is noted after 1 minute<\/li><li>inject over 1 minute; discard any unused portion<\/li><\/ul>"},"10":{"id":"930219-s-10","title":"Monitoring","mono":"signs and symptoms of an allergic reaction during administration of the secretin test dose <br\/>"},"11":{"id":"930219-s-11","title":"How Supplied","mono":"<b>Chirhostim<\/b><br\/>Intravenous Powder for Solution: 16 MCG<br\/>"},"13":{"id":"930219-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause flushing, increased heart rate, or mild pancreatitis.<\/li><li>This drug may also cause gastrointestinal effects, including nausea, abdominal pain, vomiting, or upset stomach.<\/li><\/ul>"}}}